Skip to Main Content

Author Details

Luca Malcovati
University of Pavia & S. Matteo Hospital
1997
216
66
PMIDPaper TitleJournal TitlePublished Year
36322930Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.Blood2023
37483562Prediction of risk for myeloid malignancy in clonal hematopoiesis.NEJM Evid2023
37620601Multiparameter prediction of myeloid neoplasia risk.Nat Genet2023
37774372Diagnosis and classification of myelodysplastic syndromes.Blood2023
37498312Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts.Clin Cancer Res2023
37726541Author Correction: Multiparameter prediction of myeloid neoplasia risk.Nat Genet2023
38091010IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.Blood Cancer Discov2023
37216690Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.Blood2023
37343663ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.Ann Oncol2023
37406166Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.Blood Adv2023
37471107VEXAS: walking on the edge of malignancy.Blood2023
36724453Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.Blood2023
36403897Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.J Allergy Clin Immunol Pract2023
36607832Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood Adv2023
36335984Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.Br J Haematol2023
36094848Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.Blood Adv2023
34545185Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.Leukemia2022
35846061Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms.EJHaem2022
35767897International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.Blood2022
35494238Deconvolution of the hematopoietic stem cell microenvironment reveals a high degree of specialization and conservation.iScience2022
35561316Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals.Blood Adv2022
36130297Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.Blood2022
35100354Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms.Blood2022
35042235Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs.Blood Adv2022
35292784Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome.Nat Cell Biol2022
33349666Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasms.Leukemia2021
33732266The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.Front Immunol2021
33564192Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.Nat Med2021
33666652Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.Blood Adv2021
34499156The journey of a thousand miles begins with 1 step.Blood2021
34459888Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality.Blood Adv2021
34568833<i>ZBTB33</i> is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing.Blood Cancer Discov2021
34681880Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.Int J Mol Sci2021
34476345The EHA Research Roadmap: Malignant Myeloid Diseases.Hemasphere2021
34476344EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT.Hemasphere2021
34387647A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS.Blood Adv2021
34592765A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.Blood Adv2021
34342292Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications.Curr Opin Hematol2021
34233450The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy.Haematologica2021
34166485Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia.Blood2021
34255818Relationship between clone metrics and clinical outcome in clonal cytopenia.Blood2021
33317262Atomic-Level Mechanism of Pre-mRNA Splicing in Health and Disease.Acc Chem Res2021
33359455Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data.J Mol Diagn2021
31171638Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.Haematologica2020
31958292EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.ESMO Open2020
31740811Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.Leukemia2020
31680297Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.Am J Hematol2020
33054132Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.Haematologica2020
32747829Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.Nat Med2020
32841339Guideline-based indicators for adult patients with myelodysplastic syndromes.Blood Adv2020
  • 1 - 50 of 216

Recommended Authors

Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Career Start Year 2015
Number of shared co-authors 8
Zhijie Wu
and Blood Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 0
Il??ana Antony-Debr??
INSERM, France Villejuif Universite Paris-Saclay
Career Start Year 2011
Number of shared co-authors 6
Alexa J Siddon
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Kim-Hien T Dao
Astex Pharmaceuticals
Career Start Year 2009
Number of shared co-authors 10
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 22
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 6
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 2
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 6
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 13
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 11
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 6
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 16
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 8
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 6
Stephen T Oh
Washington University School of Medicine
Career Start Year 2001
Number of shared co-authors 14
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 5
Sze Fai Yip
Tuen Mun Hospital
Career Start Year 1999
Number of shared co-authors 1
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 18
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 8
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 26
Suzanne M Vercauteren
Clinical Immunology Lab, BC Children's Hospital
Career Start Year 1996
Number of shared co-authors 0
Alison R Moliterno
Johns Hopkins Hospital
Career Start Year 1995
Number of shared co-authors 6
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 11
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 4
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 20
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 7
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 17
Clayton A Smith
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 1
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 5

Collaborators

Seishi Ogawa
Kyoto University
Co-authored papers 18
Peter J Campbell
Wellcome Sanger Institute
Co-authored papers 14
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 13
Joop H Jansen
Co-authored papers 11
Benjamin L Ebert
Co-authored papers 10
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 9
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Co-authored papers 8
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 8
Lucy A Godley
The University of Chicago
Co-authored papers 7
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 7
Bert A van der Reijden
Co-authored papers 6
Donna Neuberg
Co-authored papers 6
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Rafael Bejar
Moores Cancer Center, university of california san diego
Co-authored papers 5
Courtney D DiNardo
UT MD Anderson Cancer Center
Co-authored papers 5
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 5
Anna L Brown
Adelaide Medical School, University of Adelaide
Co-authored papers 5
Dietger Niederwieser
University of Leipzig
Co-authored papers 5
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 4
Michael Heuser
Hannover Medical School
Co-authored papers 4
Felicitas Thol
Hannover Medical School
Co-authored papers 4
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 4
Robert Kralovics
Medical University of Vienna
Co-authored papers 4
Satoru Miyano
Tokyo Medical and Dental University
Co-authored papers 4
Laura Mudie
Wellcome Trust Sanger Institute
Co-authored papers 3
Melanie M van der Klauw
Co-authored papers 3
Siddhartha Jaiswal
Co-authored papers 3
Jonathan Hinton
Inivata Ltd
Co-authored papers 3
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Co-authored papers 3
Catherine Klersy
Biostatistics & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo
Co-authored papers 3
Release 1.2